AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

Patients on Enhertu followed by a chemotherapy and dual anti-HER2 regimen fared better than those on standard therapy.

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

(RTTNews) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L, AZN), Plus ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. Ohio ...